KeraNetics awarded $1.4M contract from the Congressionally Directed Medical Research Program for use of KeraGenics Bone for military bone injuries

Winston-Salem, N.C., July 17, 2015 – KeraNetics LLC announced today that it has been awarded a $1.4M Congressionally Directed Medical Research Program (CDMRP) contract under the Department of Defense Joint Warfighter Medical Research Program for pre-clinical testing of KeraGenics Bone for the treatment of segmental bone defects.  Dr. Burnett, Chief Science Officer for the company and Principal Investigator for the project, said: “Segmental bone defects are a common injury in our Wounded Warriors and are also a clinical issue relevant to civilian trauma patients.  This project will complete dosing and efficacy studies needed to support a request to FDA for an initial meeting prior to conducting a clinical trial”

KeraNetics has conducted a significant amount of research in the area of bone regeneration, with funding from DoD Small Business Innovation Research and CDMRP contracts.  Dr Burnett stated: “We are grateful for the generous funding from the Department of Defense that allows us to complete this work.  Our preclinical studies show that this product produces robust bone regeneration in a segmental bone defects with an improved safety profile.”

About KeraNetics – KeraNetics is the global leader in the development and manufacturing of purified keratin medical products.  Headquartered in Winston-Salem, NC, KeraNetics is developing first-in-class therapeutic medical products utilizing keratin biomaterials.  For more information, visit www.keranetics.com or contact the company at info@keranetics.com.